Evercore ISI raises Illumina stock price target on strong results By Investing.com

Evercore ISI raised its price target on Illumina to $155 from $150 and kept an Outperform rating after a solid quarter featuring 20% clinical growth, a record backlog up 20%, and gross margin of 68%. The firm said the above-consensus Q2 guidance and strong free cash flow conversion above 140% reduce concern about demand pull-forward, with tariff refunds potentially aiding EPS. Illumina’s stock was already trading at $165.65, above the new target, after a 106% gain over the past year.

Analysis

ILMN is starting to look less like a mean-reversion bounce and more like a self-funding de-risking story: strong backlog plus unusually high cash conversion creates room for management to lean into execution without needing macro help. The key second-order effect is that a “good enough” diagnostics environment may be sufficient for multiple expansion if investors start treating the company as a durable free-cash-flow compounder rather than a cyclical tools name. That shift matters because the stock has already re-rated sharply; the next leg is likely driven by estimate revisions, not multiple expansion alone.

The market may be underestimating how much margin durability can offset demand volatility over the next 2-3 quarters. If tariff refunds or other transitory items boost EPS, the headline beat can persist longer than the underlying end-market recovery, which tends to pull forward consensus upgrades and force short covering. Competitively, a firmer ILMN print pressures smaller genomics tool peers and adjacent life-science vendors by signaling that capital spending is not collapsing, but rather concentrating toward the highest-credibility platform.

The risk is that the current setup becomes a textbook disappointment trade if guidance proves too optimistic heading into the next print. At ~30x 2026E earnings, the stock is now priced for sustained execution; a single quarter of backlog deceleration or margin normalization could compress multiple 15-20% quickly. The contrarian view is that the upside from here is less about business acceleration and more about the market slowly admitting that the worst-case diagnostics narrative was overstated; if that narrative already changed, near-term upside may be more limited than the after-hours reaction suggests.

Key Decisions for Investors

• Tactically stay long ILMN for 4-8 weeks only if you expect estimate revisions to continue; the setup favors a momentum/earnings-upgrade trade, but risk-reward deteriorates quickly if the next data point disappoints.
• Sell downside protection via ILMN put spreads rather than chasing upside outright; the stock is already above the raised target, so defined-risk income capture makes more sense than naked longs at these levels.
• For a relative-value expression, pair long ILMN vs. short a weaker genomics/tool name with lower cash conversion and less backlog visibility over the next 1-2 quarters; the market should reward the company with the cleanest FCF conversion first.
• If holding ILMN from lower levels, consider trimming 25-35% into strength and keeping a residual core position; the rerating appears partly complete, but operational confirmation could support a slower grind higher over the next 6-12 months.
• Avoid initiating fresh longs into an earnings gap unless volume confirms follow-through; after a >100% one-year move, post-print enthusiasm can fade fast if buy-side positioning is already crowded.